). Antitumor response for 28 evaluable patients was similar for both CBV regimens: 87 and 75% (P = 0.39). At 7.2 years, actuarial overall survival (OS), progression-free survival (PFS) and event-free survival (EFS) for the whole series were 51.7؎8%, 34؎9% and 28؎8%, with a median follow-up for the surviving patients of 3 years (0.7-7.6). No differences in these survival functions according to the CBV regimen used were observed (P = 0.57). A history of a prior CR (P = 0.003), duration of first CR Ͼ1 year (P = 0.04), absence of bulky nodal disease at transplant (P = 0.054), absence of extranodal disease at transplant (P = 0.01), and a CR status at transplant (P = 0.0006) were associated with a better PFS on univariant analysis. On multivariate analysis, only CR status at transplant remained significant (P = 0.05). When patients in second CR at transplant and those in first sensitive relapse were analyzed separately, no differences in clinical characteristics or in treatment received pretransplant were observed; however, PFS was significantly different (P = 0.01). In conclusion, CR status at transplant is useful in identifying 'good risk' patients and is necessary to obtain the greatest benefit from ASCT independent of the CBV regimen used.
Currently, 30-40% of patients with Hodgkin's disease (HD) do not respond, or relapse after an initial remission with the available first-line chemotherapy treatments. 1, 2 The choice between conventional second-line therapies or highdose chemotherapy and autologous stem cell transplant (ASCT) remains uncertain, although recently, ASCT has emerged as the approach that offers the best chance of controlling the disease. [2] [3] [4] [5] Progression-free survival (PFS) reported with ASCT varies from 30 to 60%, reflecting the different characteristics of patients included in the studies. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Several factors have been detected as predictors of a poorer outcome following ASCT. These include systemic symptoms 8, 9, 19 or extranodal disease at relapse, 9 ,19 a higher number of prior treatment regimens pretransplant, 7, 11, 15, 16 tumor bulkiness at transplant 7, 12, 13, 15, 19 and performance status at transplant. 8, 15, 16 However, they have not been uniformly confirmed in the reported literature. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Also, treatment approach when a patient is considered a candidate for transplantation is not uniform. Some authors administer chemotherapy prior to ASCT in order to achieve a status of minimal disease, 12, 13, 19, 21, 22 while others proceed directly to ASCT. 7, 8, 10, 23 Since 1986, 49 patients with HD have undergone ASCT in our Department. Preliminary analysis with the standard CBV regimen 24 showed a low PFS, so we decided to introduce a higher-dose regimen, using the same drugs, in order to increase the antitumor effect and to attain more sustained remissions in our patients.
Patients and methods
From October 1986 to April 1996, 49 consecutive patients with poor prognosis HD were transplanted in our Department. The following criteria were considered when accepting a candidate for ASCT: (1) need for two complete chemotherapy schedules to achieve CR status (five patients); (2) achievement of a partial response (five patients), or disease progression (four patients) after firstline chemotherapy; (3) relapse after obtaining a CR of short duration (17 patients); (4) relapse after a CR obtained with chemotherapy of Ͼ4 drugs independent of response duration (six patients); (5) second and later relapses (five and one patient, respectively); and (6) long lasting first CR without achievement of a second CR with conventional salvage therapy (four patients). Also, absence of active hepatic 780 disease, normal renal, cardiac and pulmonary function and good performance status (Zubrod р2) were required before acceptance for transplantation. Two patients were transplanted in first CR after one chemotherapy schedule and they have been excluded from this analysis.
The median age of 47 patients (28 males and 19 females) at transplant was 28 years (13 to 60 years). Patients' clinical characteristics at diagnosis and at ASCT are shown in Tables 1 and 2 , respectively, and they were grouped according to the CBV regimen used. Most of the characteristics were homogeneously distributed between the two conditioning regimens, except for a marginally higher proportion of CR patients at transplant in the increased CBV group (P = 0.058) and a significantly higher proportion of patients with bulky nodal disease in the standard CBV group (P = 0.025).
Cytoreductive treatment before transplantation
Cytoreductive chemotherapy was administered to 31 of 33 patients before transplant with the intention of testing chemosensitivity and reducing tumor burden. Type of cytoreductive treatment depended on the prior chemotherapy administered. Sixteen patients received DHAP or DHAPlike regimens, a median of four cycles (range 2 to 6); six received MOPP, ABVD or MOPP/ABVD, a median of six cycles (range 4 to 12); two patients EPOCH (four and six cycles); one patient CEP; five patients received combinations of two different chemotherapy regimens (MOPP or ABVD combined with DHAP or EPOCH), a median of Five patients also received additional local radiotherapy at a median of 30 Gy (range 10 to 34 Gy) over various areas: cervical, left main bronchus and cranial base, sacrum, dorso-lumbar spine (D11-L3) and mediastinum. One patient with disease progression after MOPP/ABV, received subtotal nodal irradiation (10.5 Gy) immediately prior to transplant.
Five patients in first CR (CR1) after two chemotherapy schedules and nine patients in second CR (CR2) at the time of transplant indication received no treatment.
Definition of disease status at transplant
Patients were considered to be in CR at transplant if there was no clinical, radiological or histological evidence of disease for at least 3 months off treatment. PR was defined as a reduction of 50% or more of previously evaluable disease for at least 3 months off treatment. Non-responsive or progressive disease were diagnosed if the reduction in measurable disease was less than 50%, or when new lesions appeared in spite of disease control elsewhere. Chemosensitive relapse was defined using Philip et al 25 criteria. This status was allocated to those patients who relapsed after a CR and received cytoreductive chemotherapy, achieving at 781 Table 2 Patients' characteristics at transplant according to the conditioning regimen least a 50% reduction in tumor mass. Four relapsed patients with no evidence of disease but who were transplanted immediately after cytoreductive treatment were also included in this group of patients. Chemoresistant relapse was defined as a reduction in tumoral mass of less than 50% after cytoreductive treatment. With these criteria, 15 patients (32%) were in CR (five in first CR and 10 in second CR). All patients in first CR had received second-line therapy because of minimal response (two patients), progressive disease (two patients) or PR (one patient) after first-line chemotherapy. The PR patient had palpable axillary disease that disappeared with the second chemotherapy course. Eight patients (17%) were in PR (seven in first PR). Patients in first PR never achieved a CR before transplant as minimal response or progressive disease was observed after first-line treatment and all of them required second-line chemotherapy. Nineteen patients (49%) had chemosensitive relapse, two (4%) patients had non-tested relapse, one patient (2%) had chemoresistant relapse and two patients (4%) had refractory disease.
Studies performed before ASCT
Complete physical examination, blood counts, serum LDH levels, liver and renal function tests, total-body CT scan and bone marrow biopsy were performed on all patients. For those patients who received cytoreductive treatment, the same studies were performed again in order to evaluate their status pre-ASCT.
Hematopoietic progenitor cell harvesting
Hematopoietic progenitor cells were obtained from bone marrow in 35 patients (74%). Harvests were performed under general anesthesia by multiple aspirations from posterior iliac crests. In 10 patients (21%) progenitor cells were collected from peripheral blood by consecutive aphereses, using a continuous flow cell separator Cobe-Spectra (COBE, Denver, CO, USA) after mobilization with rhG-CSF (Filgrastim, Neupogen; Amgen, Thousand Oaks, CA, USA) at a dose of 5 g/kg/day subcutaneously until the end of collection, starting apheresis on the fifth day. In both situations, progenitor cells were processed, cryopreserved in a solution with 10% DMSO and stored at Ϫ196°C in liquid nitrogen until transplantation. In two patients (4%) bone marrow and peripheral blood progenitor cells were collected for transplantation, due to a low number of progenitors in the bone marrow harvested. 
Conditioning regimen for transplantation

General management during transplant
All patients were nursed in reversed-barrier isolation during transplantation. No antibiotic or antiviral prophylaxis was given except for oral nystatin. Management of febrile episodes was according to the antibiotic protocols in use in the Department. All cellular blood products transfused posttransplant were irradiated to 25 Gy. Treatment with rhG-CSF (Filgrastim, Neupogen; Amgen), at a dose of 300 g/day from day 0, was administered to 11 patients receiving the increased CBV regimen with bone marrow support in nine patients and peripheral blood stem cells in two patients.
Additional treatment post-transplant
Eight patients were irradiated post-transplant. Four patients received radiotherapy to sites of prior bulky disease, and four patients to non-bulky nodal areas previously affected.
Follow-up after transplantation
Antitumor response was evaluated 3 months post-transplant by means of clinical examination, biochemical profiles and radiological studies as mentioned above. Since then, patients have been followed at 4-month intervals for the first year, at 6 month intervals during the second and the third year and then annually.
Definition of variables and statistical analysis
Overall survival was calculated from the time of stem cell infusion until death or last follow-up. Progression-free survival (PFS) was calculated from the time of stem cell infusion until date of relapse or progression and patients without evidence of disease were censored at time of last follow-up. Event-free survival (EFS) was calculated from the time of stem cell infusion until death (whatever the cause), relapse, progression or the occurrence of second neoplasia. Date of last evaluation was January 1997.
Regarding patient characteristics, comparisons between quantitative variables were made using the Mann-Whitney U test. For categorical variables, comparison between groups were performed by contingency table 2 analysis and Fisher's exact test for two by two tables. Survival functions were calculated by means of the method of KaplanMeier and differences between them were compared by the log-rank test. The effect of variables that could potentially influence PFS were examined by multivariate analysis using Cox regression models. Variables with an univariate P value of less than 0.1 by log-rank test were added stepwise to the model. All analyses were performed using SPSS 6.1 (SPSS Inc, Chicago, IL, USA) and Statview 4.0 (Abacus Concepts Inc, Berkeley, CA, USA) software packages on a Macintosh personal computer.
Results
Survival
At 7.2 years actuarial overall survival (OS), progressionfree survival (PFS) and event-free survival (EFS) for the whole series were 51.7% (CI: 0.95; 36.1-67.3), 34% (CI: 0.95; 16.4-51.5) and 28% (CI: 0.95; 12.4-43.6), with a median follow-up for the surviving patients of 3 years (0.7 to 7.6 years) (Figure 1) . At 4.6 years actuarial PFS for standard and increased CBV regimens were 29% (CI: 0.95; 8-50) and 47% (CI: 0.95; 26-68), respectively (P = 0.57) (Figure 2 ).
Events
Nineteen patients have died: four patients because of early toxic death (three due to Pneumonia caused by mycoplasma (1), Aspergillus fumigatus (1) and idiopathic (1) and one patient due to septic shock of abdominal origin); one patient of late sudden death in CR at 7 years post-transplant and 14 patients due to disease progression. Two patients are alive but with poor performance status due to the occurrence of second neoplasia (one non-Hodgkin's lymphoma and one myelodysplastic syndrome) and nine patients are currently alive but with active HD. Events were similar between the two conditioning regimens. Two out of 22 (8%) patients died early in the standard CVB group vs two out of 25 (9%) patients in the increased CBV group (P = 0.9). Regarding late events, one second neoplasia and the sudden death occurred in the standard CBV group and the other neoplasia occurred in the increased CBV group.
Hematological recovery
Hematological recovery for the 43 evaluable patients was as follows: median times to reach an absolute neutrophil count у0.5 ϫ 10 9 /l and у1 ϫ 10 9 /l were 14.5 days (10-50) and 18 days (10-50), respectively, and the median times to recover a platelet count у20 ϫ 10 9 /l and у50 ϫ 10 9 /l were 20 days (8-270) and 24 days (11-96), respectively. No differences in granulocyte and platelet recovery were observed between regimens.
Antitumor response
Twenty-eight out of 32 patients with active HD were evaluable for response. Fifteen patients in CR at transplant and four patients who died early were excluded. Thirteen of 28 (46%) achieved a CR, 10 (36%) a PR and five (18%) progressed. No differences in response rates were observed between either CBV regimen: 14 patients out of 16 (87%) and nine patients out of 12 (75%) achieved a CR or PR after transplant, respectively (P = 0.39). In five patients (two in PR and three in CR), response was evaluated after receiving adjuvant post-transplant radiotherapy. 
Consolidative radiotherapy post-transplant
Three patients in CR at transplant, received radiotherapy as consolidation treatment over areas of bulky disease (two patients) or over nodal areas affected at last pre-transplant relapse (one patient).
Statistical analyses
The variables shown in Tables 1 and 2 were analyzed for their influence on PFS post-transplant. The type of con- ditioning regimen used was also included in the analysis. Univariant analysis identified the variables shown in Table  3 as being significantly associated with PFS. None of the characteristics at diagnosis had a significant impact on PFS; only a history of a prior CR and duration of CR of more than 1 year for responders to first-line therapy were associated with increased PFS. Regarding the characteristics at transplant, bulky nodal disease and extranodal disease at transplant, and the absence of CR status pretransplant were associated with a poorer PFS. Type of conditioning regimen did not influence PFS. Furthermore, PFS curves were similar when comparing both CBV regimens in patients transplanted with active disease (P = 0.9). Multivariate analysis was performed on the following variables: extranodal and bulky nodal disease at transplant and status at transplant. Only status of disease at transplant remained significant ( Figure 3 ). Since CR status pre-ASCT was the most important variable affecting PFS in this series, we analyzed the group of patients who relapsed after a first CR and compared the clinical characteristics between those who achieved a second CR (10 patients) and those in first sensitive relapse (15 patients) at the time of transplant. No significant differences between these groups of patients, could be detected (Table 4) . However, the median duration of PFS was 9 months for patients in first sensitive relapse, whereas the likelihood of progression never reached 50% in patients transplanted in second CR (P = 0.01).
Discussion
There is great consensus regarding the use of high-dose chemotherapy and autografting as the treatment of choice for patients with HD in relapse 9, 10, 15, 16 or who do not achieve CR with first-line chemotherapy.
12,20 Although secondline chemotherapy and autologous transplantation (ASCT) have not been extensively compared in a prospective manner, comparative results of pilot studies 5 and recent series of ASCT 9, 10, 11, 19 with historical series using second-line chemotherapy, 2 strongly suggest that ASCT offers signifi- cantly better disease control. In a recent retrospective study, the Standford group 3 compared conventional salvage chemotherapy and ASCT and found a better PFS and EFS for the ASCT group, although the clearly significant advantage was observed among patients with refractory disease and those with remissions of short duration.
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In our series, actuarial PFS at 7 years was 34%, which compares with previously reported data, 7, 10, 11, 15, 16 especially if we take into account that 19% of our patients never achieved CR pretransplant and 55% of relapsing patients had a duration of CR of less than 1 year.
The impact of high-dose chemotherapy on overall survival remains more controversial and, in this sense, no author has proven a significant benefit of ASCT over salvage chemotherapy. Longer follow-up periods for patients undergoing ASCT are necessary to assess the real impact of ASCT on survival. In our series, the 7.2 years actuarial overall survival was 51.7%, but the occurrence of toxic events and of second neoplasias has determined an EFS of only 28%. Early toxic death rates have tended to decrease with ASCT due to better timing of transplantation, but the ocurrence of late toxic events 26 after ASCT compared with those occurring after conventional chemotherapy will determine the real impact of ASCT on survival in the future.
In this series, the use of a more intensive conditioning regimen did not yield an improvement in results. The higher dose CBV regimen increased doses of cyclophosphamide by 20%, BCNU by 46% and etoposide by 200%. However, no differences in antitumoral response rates, PFS and EFS were observed between regimens. Furthermore, patients who received the standard-dose CBV regimen appeared to have a poorer prognosis due to a lower proportion of patients being in CR and a higher proportion of patients having bulky nodal disease at transplant.
To our knowledge, the efficacy of different conditioning regimens used for autografting in HD, has not been prospectively compared. Only the Standford group 19 has published the results of a non-randomized study with prospective assignation to patients at three conditioning regimens, and they observed no differences in OS, EFS and PFS. In other retrospective studies, no conditioning regimen has demonstrated superior efficacy, 9, 17 including those containing total body irradiation. 11, 19 In our series, the characteristics associated with a better PFS are similar to those previously reported, and include a prior history of CR, 13 longer duration of first CR, 9 absence of bulky nodal disease at transplant, 7, 12, 13, 19, 21 absence of extranodal disease at transplant 11 and disease status at transplant. 7, 12, 13, 15, 19 Of these, absence of disease or a minimal disease status at transplant is one of the most frequently published independent factors with prognostic significance. 7, 12, 13, 15, 19 Our results support that administration of salvage chemotherapy with the intention of achieving CR status pretransplant, is necessary for the greatest benefit from ASCT. It is also useful for identifying groups of patients with a clearly different post-transplant outcome. In our series, outcome of patients in second CR was significantly better when compared with patients in first relapse. It may be argued that achieving CR status at transplant may reflect a more benign disease with increased chemosensitivity. In this sense, both 785 Table 4 Comparison between patients relapsing after a first CR according to status at transplant groups of patients showed comparable clinical characteristics, previous treatments and response duration. The quality of response at the time of transplant was the only different variable observed. Unfortunately, it seems that such antitumor response can not be predicted.
In conclusion, we believe that CR status pretransplant is necessary prior to high-dose chemotherapy in order to achieve long-term disease control. In this series, the intensified CBV regimen has not improved the results of ASCT.
